Hepatitis A: Disease Burden and Current Childhood Vaccination Strategies in the United States

Journal of Pediatric Health Care

Volumn 22, Issue 1, 2008, Pages 3-11

  Koslap Petraco, Mary Beth ^a   Shub, Mitchell ^a   Judelsohn, Richard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

AGED; ARTICLE; CHILD; COST OF ILLNESS; DISEASE TRANSMISSION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SURVEY; HEPATITIS A; HOSPITALIZATION; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MASS IMMUNIZATION; METHODOLOGY; MORBIDITY; ORGANIZATION AND MANAGEMENT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; RISK FACTOR; SOCIOECONOMICS; STATISTICS; UNITED STATES; VACCINATION;

AGED; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DRUG APPROVAL; HEALTH PLANNING GUIDELINES; HEALTH POLICY; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; MASS IMMUNIZATION; MORBIDITY; POPULATION SURVEILLANCE; PUBLIC HEALTH; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINATION;

EID: 37448999343     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedhc.2006.12.011     Document Type: Article

References (57)

1. Agarwal K.S., Puliyel J.M., Mathew A., Lahoti D., and Gupta R. Acute pancreatitis with cholestatic hepatitis: An unusual manifestation of hepatitis A. Annals of Tropical Paediatrics 19 (1999) 391-394
2. Armstrong G.L., and Bell B.P. Hepatitis A virus infections in the United States: Model-based estimates and implications for childhood immunization. Pediatrics 109 (2002) 839-845
3. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine 144 (2006) 705-714
4. Basaranoglu M., Balci N.C., and Klor H.U. Gallbladder sludge and acute pancreatitis induced by acute hepatitis A. Pancreatology 6 (2006) 141-144
5. Bell B.P. Global epidemiology of hepatitis A: Implications for control strategies. In: Margolis H.S., Alter M.J., Liang J., and Dienstag J. (Eds). Viral hepatitis and liver disease (2002), International Medical Press, Atlanta 9-14. http://www.cdc.gov/ncidod/diseases/hepatitis/a/global_hepA_epi.pdf Retrieved from http://www.cdc.gov/ncidod/diseases/hepatitis/a/global_hepA_epi.pdf
6. Bell B.P., Anderson D.A., and Feinstone S.M. Hepatitis A virus. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th ed. (2005), Churchill Livingstone, Philadelphia 2162-2185
7. Bialek S.R., Thoroughman D.A., Hu D., Simard E.P., Chattin J., Cheek J., et al. Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001. American Journal of Public Health 94 (2004) 996-1001
8. Brown G.R., and Persley K. Hepatitis A epidemic in the elderly. Southern Medical Journal 95 (2002) 826-883
9. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 1995. Morbidity and Mortality Weekly Report 44 (1995) 1-87
10. Centers for Disease Control and Prevention. Notice to readers: Licensure of inactivated hepatitis A vaccine and recommendations for use among international travelers. Morbidity and Mortality Weekly Report 44 (1995) 559-560
11. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 45 RR-15 (1996) 1-30
12. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 48 RR-12 (1999) 1-37
13. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 60 (2005), U.S. Department of Health and Human Services, Atlanta, GA
14. Centers for Disease Control and Prevention. Record of the meeting of the Advisory Committee on Immunization Practices (2005) October 26-27
15. Centers for Disease Control and Prevention. Hepatitis A vaccination coverage among children aged 24-35 months-United States, 2003. Morbidity and Mortality Weekly Report 54 (2005) 141-144
16. Centers for Disease Control and Prevention. Notice to readers: FDA approval of Havrix (hepatitis A vaccine, inactivated) for persons aged 1-18 years. Morbidity and Mortality Weekly Report 54 (2005) 1235-1236
17. Centers for Disease Control and Prevention. Notice to readers: FDA approval of VAQTA (hepatitis A vaccine, inactivated) for children aged ≥1 year. Morbidity and Mortality Weekly Report 54 (2005) 1026
18. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 55 RR-7 (2006) 1-23
19. Centers for Disease Control and Prevention. Hepatitis A. Epidemiology and prevention of vaccine-preventable diseases. 9th ed. (2006), Author, Atlanta, GA 193-206 (pink book)
20. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2004. Morbidity and Mortality Weekly Report 53 (2006) 1-81
21. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, 2006. Morbidity and Mortality Weekly Report 54 (2006) +Q4
22. Dagan R., Leventhal A., Anis E., Slater P., Ashur Y., and Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. Journal of American Medical Association 294 (2005) 202-210
23. Domenech P., Palomeque A., Martinez-Gutierrez A., Vinolas N., Vela E., and Jimenez R. Severe aplastic anaemia following hepatitis A. Acta Haematologica 6 (1986) 227-229
24. Elinav E., Ben-Dov I.Z., Shapira Y., Daudi N., Adler R., Shouval D., et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 130 (2006) 1129-1134
25. Erkan T., Kutlu T., Cullu F., and Tumay G.T. A case of vertical transmission of hepatitis A virus infection. Acta Paediatrica 87 (1998) 1008-1009
26. Fiore A.E. Hepatitis A transmitted by food. Clinical Infectious Diseases 38 (2004) 705-715
27. Gall S.A. Expanding the use of hepatitis vaccines in obstetrics and gynecology. American Journal of Medicine 118 (2005) 96S-99S
28. Grey M. The impact of the "Put Prevention into Practice" initiative on pediatric nurse practitioner practices. Journal of Pediatric Health Care 12 (1998) 171-175
29. Hadler S.C., Webster H.M., Erben J.J., Swanson J.E., and Maynard J.E. Hepatitis A in day-care centers. A community-wide assessment. New England Journal of Medicine 302 (1980) 1222-1227
30. Hamer D.H., and Connor B.A. Travel health knowledge, attitudes and practices among United States travelers. Journal of Travel Medicine 11 (2004) 23-26
31. Hutin Y.J., Pool V., Cramer E.H., Nainan O.V., Weth J., Williams I.T., et al. A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. New England Journal of Medicine 340 (1999) 595-602
32. Inman R.D., Hodge M., Johnston M.E., Wright J., and Heathcote J. Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Annals of Internal Medicine 105 (1986) 700-703
33. Jamil S.M., and Massry S.G. Acute anuric renal failure in nonfulminant hepatitis A infection. American Journal of Nephrology 18 (1998) 329-332
34. Keeffe E.B. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. American Journal of Medicine 118 (2005) 21S-27S
35. Laurence J.C. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. American Journal of Medicine 118 (2005) 75S-83S
36. Lednar W.M., Lemon S.M., Kirkpatrick J.W., Redfield R.R., Fields M.L., and Kelley P.W. Frequency of illness associated with epidemic hepatitis A virus infections in adults. American Journal of Epidemiology 122 (1985) 226-233
37. Nolan T., Bernstein H., Blatter M.M., Bromberg K., Guerra F., and Kennedy W. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics 118 (2006) e602-e609
38. Roessling G. Prefilled syringes: Innovations that meet the growing demand. ONdrugDelivery Ltd, UK. Retrieved September 11, 2006, from (2005). http://www.ondrugdelivery.com/publications/prefilled_syringes.pdf
39. Schiff E.R. Atypical clinical manifestations of hepatitis A. Vaccine 10 (1992) S18-S20
40. Sewell E.C., Jacobson S.H., and Weniger B.G. "Reverse engineering" a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines. Pediatric Infectious Disease Journal 20 (2001) S45-S56
41. Shenoy R., Nair S., and Kamath N. Thrombocytopenia in hepatitis A-an atypical presentation. Journal of Tropical Pediatrics 50 (2004) 241-242
42. Shepard C.W., Ortega-Sanchez I.R., Scott R.D., and Rosenstein N.E. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115 (2005) 1220-1232
43. Shroff G.R., Badve S.V., Joshi A.G., Desai D.C., Abraham P., and Sirsat R.A. Acute renal tubular injury with acute hepatitis A infection: is it just a coincidence?. Nephrology 9 (2004) 44-46 (Carlton)
44. Staes C.J., Schlenker T.L., Risk I., Cannon K.G., Harris H., Pavia A.T., et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 106 (2000) E54
45. Steffen R. Changing travel-related global epidemiology of hepatitis A. American Journal of Medicine 118 Suppl 10A (2005) 46S-49S
46. Tomida S., Matsuzaki Y., Nishi M., Ikegami T., Chiba T., Abei M., et al. Severe acute hepatitis A associated with acute pure red cell aplasia. Journal of Gastroenterology 31 (1996) 612-617
47. Tyler K.L., Gross R.A., and Cascino G.D. Unusual viral causes of transverse myelitis: Hepatitis A virus and cytomegalovirus. Neurology 36 (1986) 855-858
48. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: Is there a need?. Lancet 362 (2003) 1065-1071
49. Van Effelterre T.P., Zink T.K., Hoet B.J., Hausdorff W.P., and Rosenthal P. A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization. Clinical Infectious Diseases 43 (2006) 158-164
50. Van Herck K., and Van Damme P. Prevention of hepatitis A by Havrix: A review. Expert Review of Vaccines 4 (2005) 459-471
51. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., and Ghironzi G. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. New England Journal of Medicine 338 (1998) 286-290
52. Vesely D.L., Dilley R.W., Duckworth W.C., and Paustian F.F. Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure. American Journal of the Medical Sciences 317 (1999) 419-424
53. Wasley A., Samandari T., and Bell B.P. Incidence of hepatitis A in the United States in the era of vaccination. Journal of the American Medical Association 294 (2005) 194-201
54. Werblowsky-Constantini N., Livshin R., Burstein M., Zeligowski A., and Tur-Kaspa R. Toxic epidermal necrolysis associated with acute cholestatic viral hepatitis A. Journal of Clinical Gastroenterology 11 (1989) 691-693
55. Wheeler C., Vogt T.M., Armstrong G.L., Vaughan G., Weltman A., Nainan O.V., et al. An outbreak of hepatitis A associated with green onions. New England Journal of Medicine 353 (2005) 890-897
56. World Health Organization. WHO Vaccine-preventable diseases: monitoring system, 2004 global and regional summary. Retrieved September 10, 2006, form (2004). http://www.who.int/immunization_delivery/systems_policy/GlobalSummary2004.pdf
57. Zhou F., Bisgard K.M., Yusuf H.R., Deuson R.R., Bath S.K., and Murphy T.V. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: An economic analysis. Pediatrics 110 (2002) 653-661